EHRA Premium Access

Long term outcome after ablation of persistent atrial fibrillation in patients with postprocedurally unmasked sinus node disease


About the speaker

Mrs Elisabeth Martini

Munich (Germany)
0 follower

6 more presentations in this session

First real-world experience with pulmonary vein isolation using pulsed field ablation for paroxysmal atrial fibrillation

Speaker: Associate Professor K. Neven (Essen, DE)


Feasibility of a novel algorithm for automated reconstruction of the left atrial anatomy based on intracardiac echocardiography

Speaker: Doctor F. Akerstrom (Stockholm, SE)


Left atrial anatomical variations correlate with atrial fibrillation sources near the left atrial ridge

Speaker: Doctor R. Gagyi (Rotterdam, NL)


Modern technologies for radiofrequency pulmonary vein isolation. Comparison of radiofrequency balloon catheter with high power-short duration ablation in patients with paroxysmal atrial fibrillation

Speaker: Doctor J. van den Bruck (Cologne, DE)


Radiofrequency ablation impact on the morpho-functional state of the heart in patients with atrial fibrillation and chronic heart failure

Speaker: Assistant Professor T. Zolotarova (Kharkiv, UA)


Access the full session

Moderated ePosters - Update on new techonologies and strategies to improve outcome of atrial fibrillation ablation

Speakers: Mrs E. Martini, Associate Professor K. Neven, Doctor F. Akerstrom, Doctor R. Gagyi, Doctor J. van den Bruck...

About the event


EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Related content

EHRA Premium Access

Impact of high-power and very high-power short-duration radiofrequency ablation on procedure characteristics and first-pass isolation during pulmonary vein isolation

5 April 2022

EHRA Premium Access

Detection of endo-epicardial atrial low-voltage areas using unipolar and omnipolar voltage mapping

3 April 2022

EHRA Premium Access

Pulsed field ablation of atrial fibrillation: recurrence rate after first pulmonary vein isolation and first insights into durability at redo procedures

3 April 2022

This platform is supported by

logo Novo Nordisk